Solvonis Therapeutics plc (LSE: SVNS), a biopharmaceutical company developing small-molecule treatments for central nervous system disorders, announced on Wednesday that it has been granted a second US patent (No. 12,595,269) covering a chemically distinct monoamine modulator series from its PTSD discovery programme. The patent, issued on 7 April 2026, protects compounds designed to target serotonin, dopamine, and noradrenaline transporters (SERT, DAT, NET) and is expected to remain in force until 16 February 2043, subject to standard maintenance and extensions.

PTSD affects over 20 million people across the UK, US and Europe, with limited pharmacological options. Solvonis' portfolio now includes two US patents for different monoamine modulator series, enhancing its chemistry estate and supporting follow-on development beyond a single lead asset. Recent milestones include the selection of SVN-114 as the lead PTSD compound, a USPTO Notice of Allowance in January 2026, and the first patent (No. 12,590,077) granted in March 2026.

Solvonis is also advancing therapies for Alcohol Use Disorder (AUD) with SVN-001 in Phase 3 in the UK and SVN-002 preparing for a Phase 2b trial in the US, alongside broader CNS discovery programmes targeting psychiatric and addiction indications. The company's patent portfolio and compound library strengthen its platform for next-generation CNS therapeutics.